<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90308">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01929408</url>
  </required_header>
  <id_info>
    <org_study_id>2368.00</org_study_id>
    <secondary_id>RSG-13-084-01-CPHPS</secondary_id>
    <nct_id>NCT01929408</nct_id>
  </id_info>
  <brief_title>Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients</brief_title>
  <official_title>Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Cancer Society, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare treatment methods and outcomes of patients diagnosed
      with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective multicenter observational study in a Consortium of collaborating
      institutions investigating how often older and medically infirm patients who are diagnosed
      with Acute Myeloid Leukemia (AML) or high-risk myelodysplastic syndromes (MDS) and treated
      with induction chemotherapy undergo allogeneic HCT. Investigators will look at the rate of
      undergoing allogeneic HCT among older and medically infirm AML and high-risk MDS patients
      compared to younger and relatively healthier patients. Investigators will also compare the
      characteristics and outcomes of patients who did versus did not proceed to allogeneic HCT. A
      number of outcomes will be assessed including mortality, morbidity, and quality of life
      (QOL). Baseline information will be collected on different domains of QOL, geriatric
      assessment, health status measures, AML features, and socioeconomic status. Information will
      help physicians and patients to decide on best treatment choices for AML and high-risk MDS
      in older and medically infirm patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Non-Relapse Mortality (NRM)</measure>
    <time_frame>2 years</time_frame>
    <description>Investigators will assess non-relapse mortality (NRM) of patients enrolled in the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Investigators will assess Overall Survival (OS) of patients enrolled in the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Investigators will assess Disease Free Survival (DFS) of patients enrolled in the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>2 years</time_frame>
    <description>QOL and symptoms will be assessed longitudinally using 7 measures covering physical, functional, social/family, emotional well-being mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and social activities.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include non-M3 AML and high-risk MDS patients considered for
        induction chemotherapy at FHCRC and the Seattle Cancer Care Alliance Network and other
        Core institutions (Stanford School of Medicine, Cleveland Clinic, Northwestern University,
        Massachusetts General Hospital, and University of Utah) in addition to an unidentified
        number of affiliate sites. We anticipate enrollment of a total sample of 1000 patients.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients with new diagnoses of non-M3 AML or high-risk MDS (showing 10% or more blasts in
        bone marrow) who:

          -  Present for an AML-like treatment that could plausibly produce a complete remission
             (CR); for example intensive induction chemotherapy, low dose single agent
             chemotherapy, hypomethylation agent, or a similar therapy

          -  Explicitly intend to establish follow-up care at one of the collaborating
             institutions.

          -  Patients with primary refractory or first relapse presenting for salvage chemotherapy
             will be allowed

          -  Patients of &gt; 18 years of age and are being treated by the adult AML service.

          -  Able to speak and read English.

          -  Willing and able to provide informed consent.

        Exclusion Criteria

          -  Patients of â‰¤17 years of age or who are &gt; 18 and receive treatment under the
             pediatric AML service.

          -  Patients older than 80 years

          -  Patients with &lt;6 months projected survival due to active second malignancy or other
             medical problem.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Sorror, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Member, FHCRC; Associate Professor of Medicine, UW</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenny Whitten, BS, BA</last_name>
    <phone>206-667-7949</phone>
    <email>jwhitten@fhcrc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shylo Wardyn, MS</last_name>
    <phone>206-667-7263</phone>
    <email>swardyn@fhcrc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Barath</last_name>
      <phone>312-695-1316</phone>
      <email>stephanie.barath@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>John Galvin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Lesho</last_name>
      <phone>410-328-2577</phone>
      <email>plesho@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Maria Baer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Cordner</last_name>
      <phone>314-747-4678</phone>
      <email>cordnert@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Tanya Wildes, MD, MSCI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Barga</last_name>
      <phone>551-996-8017</phone>
      <email>kbarga@hackensackumc.org</email>
    </contact>
    <investigator>
      <last_name>Stefan Faderl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Bashaw</last_name>
      <phone>716-845-4971</phone>
      <email>heather.bashaw@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Eunice Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Hoyle</last_name>
      <phone>919-668-1016</phone>
      <email>julia.hoyle@duke.edu</email>
    </contact>
    <investigator>
      <last_name>David Rizzieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Hoeflinger</last_name>
      <phone>216-636-5646</phone>
      <email>hoeflip@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Aaron Gerds, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manasi Vinod</last_name>
      <phone>215-614-1812</phone>
      <email>manasi.vinod@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Selina Luger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kolleen Hicks</last_name>
      <phone>801-581-4467</phone>
      <email>Kolleen.Hicks@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Shami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FHCRC</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Whitten, BS, BA</last_name>
      <phone>206-667-7949</phone>
      <email>jwhitten@fhcrc.org</email>
    </contact>
    <contact_backup>
      <last_name>Shylo Wardyn, MS</last_name>
      <phone>206-667-7263</phone>
      <email>swardyn@fhcrc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mohamed Sorror, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCCA Network Clinics</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SCCA Network Research Office General Line</last_name>
      <phone>206-288-7232</phone>
    </contact>
    <investigator>
      <last_name>Jack Hensold, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Rado, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Troy Wadsworth, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Kummet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeanne Anderson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aimee Kohn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kiarash Kojouri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mitchell Garrison, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 1, 2017</lastchanged_date>
  <firstreceived_date>August 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
